TOGETHER WE HAVE ACHIEVED, 2000–2023

>1.1BILLION CHILDREN
vaccinated through routine programmes
>1.9BILLION VACCINATIONS
through preventive vaccination campaigns
>18.8MILLION
future deaths averted
Dr Sania Nishtar

Welcome to Gavi’s 2023 Annual Progress Report, the third of Gavi’s 2021–2025 strategic period (Gavi 5.0/5.1). 2023 marked the end of the COVID-19 pandemic and the launch of innovative tools to help ensure a rapid, equitable response to vaccine-preventable disease outbreaks. The Alliance intensified efforts to support countries in restoring routine immunisation and catching up missed children.

- Dr Sania Nishtar, Gavi CEO

Progress seen in 2023 is a testament to the power of the Vaccine Alliance

Since Gavi was established in 2000 with a mission to save lives, reduce poverty and protect the world against the threat of epidemics and pandemics, it has helped vaccinate more than 1.1 billion children in 78 countries through the end of 2023 – averting more than 18.8 million future deaths.

The progress seen in 2023 is a testament to the power of the Vaccine Alliance – from our core partners to the dedicated, passionate people in countries and communities upon whose hard work and expertise we rely every day to protect the next generation. The Alliance maintains a relentless focus on reaching the 11 million ‘zero-dose’ children who did not receive a single shot of basic vaccines in 2023.

As the core of Gavi’s work, life-saving immunisation represents a beacon of hope in these uncertain times: the foundation for the healthy future every child deserves, and on which our interconnected world depends.

Highlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.

Annual Progress Report 2023

Highlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.

Download report

Highlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.

Download report

Gavi 5.0/5.1 mission and strategic goals

“Leaving no one behind with immunisation” is Gavi’s vision.

The Vaccine Alliance’s mission is: to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. Six “mission indicators” reflect our overall progress against our aspirations for the 2021–2025 period. 

This mission is also supported by the following four strategic goals, each with its own set of strategy indicators.

Introduce and scale up vaccines

With the exception of pentavalent vaccine, in aggregate all Gavi‑supported vaccines had higher coverage in 2023 than before the pandemic in 2019.
 

Learn more

56 %

The 57 Gavi-supported countries increased breadth of protection with vaccines in the Gavi portfolio to 56%, up 3 percentage points from 2022.

Strengthen health systems to increase equity in immunisation

In Gavi 5.0/5.1, health system strengthening (HSS) support prioritises equity in immunisation delivery, to reduce the number of zero-dose and under-immunised children. 
 

Learn more

80 %

In 2023, Gavi-supported countries maintained DTP3 coverage at 80% (compared to the 84% global average).

Improve sustainability of immunisation programmes

The year 2023 confirmed the robustness of the Vaccine Alliance’s co-financing approach and the steady financial commitment of countries, despite many countries facing increasing fragility. 
 

Learn more

US$ 1.7bn by end 2023

In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2023, bringing to US$ 1.7 billion their total contribution since the introduction of the co-financing policy in 2008.

Ensure healthy markets for vaccines and related products

Gavi’s market shaping efforts make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries. 
 

Learn more

19

Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines remained at 19 in 2023 (with more than half based in low- and middle-income countries) – compared with 5 in 2001.

Related articles

View all

The Vaccine Alliance in 2023

Prof José Manuel Barroso, Chair of the Gavi Board, and Dr Sania Nishtar, CEO of Gavi since 18 March 2024, reflect on the driving forces of progress in 2023 and plans for 2024.

Gavi's impact in 2023 in seven key statistics

In the time it takes you to read this article, six people’s lives will have been saved by Gavi-supported vaccines. Here are seven statistics on Gavi’s impact in 2023.

Gavi’s impact on the world in 2022: 7 key statistics

Gavi’s 2022 Annual Progress Report highlights the impact of investment in immunisation across 57 Gavi-supported countries.

On the road to recovery in 2022, a year of renewal in 2023

Prof José Manuel Barroso, Chair of the Gavi Board, and Gavi CEO (ad int) David Marlow on achievements and challenges in 2022, and priorities and goals for 2023.

APR 2021: 1.2 million future deaths prevented, 65 million children newly protected

Gavi’s 2021 Annual Progress Report, released today, is a record in numbers of another difficult pandemic year – a year of alarming setbacks, and a year of hard-won gains.

APR 2021: Recognising country commitment

Prof José Manuel Barroso, Chair of the Gavi Board, reflects on the achievements of lower-income countries during the pandemic.

APR 2021: Reflecting on 2021, the global imperative for 2022

Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, looks back on the first year of Gavi 5.0

Five crucial years, one unprecedented new pandemic and 324 million children immunised

Even with the adversities and challenges of the COVID-19 pandemic through 2020, Gavi maintained unyielding focus on leaving no one behind.

Routine immunisation worldwide holds firm despite the pandemic

Despite the havoc wrought by the COVID-19 pandemic on health systems worldwide, governments’ work to bring immunisation programmes back on track is paying off.

Empowering countries to self-finance vaccines

A growing number of countries are transitioning out of Gavi support. Here’s how we help them sustainably finance and manage their vaccine programmes over the long term.

Past progress reports

View all

Gavi Progress Report 2023

Welcome to Gavi’s 2023 Annual Progress Report, the third of the 2021–2025 strategic period.

Gavi Progress Report 2022

Welcome to Gavi’s 2022 Annual Progress Report, the second of the 2021–2025 strategic period.

Gavi Progress Report 2021

Welcome to Gavi’s 2021 Annual Progress Report, the first of the 2021–2025 strategic period.

Gavi Progress Report 2020

Welcome to Gavi’s 2020 Annual Progress Report, the fifth in a series of five covering this strategic period.

Gavi Progress Report 2019

Welcome to Gavi’s 2019 Annual Progress Report, the fourth in a series of five covering this strategic period.

Last updated: 1 Oct 2024

Subscribe to our newsletter